cp-154526 and Hypoxia

We have shown that hypoxia reduces plasma insulin, which correlates with corticotropin-releasing hormone (CRH) receptor 1 (CRHR1) in rats, but the mechanism remains unclear. Here, we report that hypobaric hypoxia at an altitude of 5,000 m for 8 h enhances rat plasma CRH, corticosterone, and glucose levels, whereas the plasma insulin and pancreatic ATP/ADP ratio is reduced. In islets cultured under normoxia, CRH stimulated insulin release in a glucose- and CRH-level-dependent manner by activating CRHR1 and thus the cAMP-dependent protein kinase pathway and calcium influx through L-type channels. In islets cultured under hypoxia, however, the insulinotropic effect of CRH was inactivated due to reduced ATP and cAMP and coincident loss of intracellular calcium oscillations. Serum and glucocorticoid-inducible kinase 1 (SGK1) also played an inhibitory role. In human volunteers rapidly ascended to 3,860 m, plasma CRH and glucose levels increased without a detectable change in plasma insulin. By contrast, volunteers with acute mountain sickness (AMS) exhibited a marked decrease in HOMA insulin sensitivity (HOMA-IS) and enhanced plasma CRH. In conclusion, hypoxia may attenuate the CRH-insulinotropic effect by reducing cellular ATP/ADP ratio, cAMP and calcium influx, and upregulated SGK1. Hypoxia may not affect HOMA-IS in healthy volunteers but reduces it in AMS volunteers.

Topics: Adenosine Triphosphate; Adolescent; Adult; Altitude; Animals; Blood Glucose; Calcium; Corticosterone; Corticotropin-Releasing Hormone; Cyclic AMP; Humans; Hydrocortisone; Hypoxia; Insulin; Male; Pancreas; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Young Adult

To determine whether corticotropin-releasing hormone receptor 1 (CRHR1) coexists with endothelin-1 (ET-1) in rat paraventricular nucleus (PVN), ET-1 expression and its regulation by CRH and CRHR1 under hypoxia, rats were exposed to simulated continuous hypoxia at 5 km altitude (CH5km, equal to 10.8% O(2)) in a hypobaric chamber for 1, 2, 5, 10, 15 or 25 days. ET-1, CRH, and its mRNA were measured using radioimmunoassay (RIA), immunohistochemistry, and in situ hybridization. The coexistence of ET-1 and CRHR1 was identified by confocal immunofluorescence. The results showed that CH5km caused a significant decrease of ET-1 level in PVN at 5 days, but decreased CRH on days 1 and 2 while it increased on days 5 and 10. CH5km induced ET-1 mRNA upregulation and ET-1 decrease at 5 days, the effects were completely reversed by treatment with five-daily-injections of a CRHR1 antagonist (butyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d] pyrimidin-4-yl]-ethylamine: CP-154,526). Also, this treatment significantly reversed the CH5km-induced increase in CRH and CRHmRNA in PVN at 5 days. Moreover we found that the changes in expression of ET-1 and CRHR1 induced by CH5km were co-localized in parvocellular PVN cells. In conclusion, CRHR1 coexists with ET-1 in parvocellular PVN, continuous hypoxia stimulates ET-1 and ET-1mRNA as well as CRH and CRHmRNA, and CRHR1 evidently modulates ET-1 release and ET-1mRNA activation caused by continuous hypoxia.

Topics: Animals; Corticosterone; Endothelin-1; Gene Expression Regulation; Hypoxia; Male; Paraventricular Hypothalamic Nucleus; Pyrimidines; Pyrroles; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; RNA, Messenger; Time Factors

To determine the influence of continuous hypoxia on body weight, food intake, hepatic glycogen, circulatory glucose, insulin, glucagon, leptin, and corticosterone, and the involvement of the corticotropin-releasing factor receptor type 1 (CRFR1) in modulation of these hormones, rats were exposed to a simulated altitude of 5 km (approximately 10.8% O2) in a hypobaric chamber for 1, 2, 5, 10, and 15 d. Potential involvement of CRFR1 was assessed through five daily sc injections of a CRFR1 antagonist (CP-154,526) prior to hypoxia. Results showed that the levels of body weight, food intake, blood glucose, and plasma insulin were significantly reduced; the content of hepatic glycogen initially and transiently declined, whereas the early plasma glucagon and leptin remarkably increased; plasma corticosterone was markedly increased throughout the hypoxic exposure of 1-15 d. Compared with hypoxia alone, CRFR1 antagonist pretreatment in the hypoxic groups prevented the rise in corticosterone, whereas the levels of body weight and food intake were unchanged. At the same time, the reduction in blood glucose was greater and the pancreatic glucose was increased, plasma insulin reverted toward control, and plasma glucagon decreased. In summary, prolonged hypoxia reduced body weight, food intake, blood glucose, and plasma insulin but transiently enhanced plasma glucagon and leptin. In conclusion, CRFR1 is potentially involved in the plasma insulin reduction and transient glucagon increase in hypoxic rats.

Topics: Altitude; Animals; Blood Glucose; Body Weight; Corticosterone; Eating; Glucagon; Hypoxia; Insulin; Leptin; Liver Glycogen; Male; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone

We have reported that, in rats, hypoxia (10.8% O2) stimulates prolactin (PRL) release from the pituitary. This study is designed to compare the response of pituitary PRL to acute hypoxia (AH), continual hypoxia (CH), intermittent hypoxia (IH), cold, and restraint, individually and combined with hypoxia. This study also investigates the involvement of the corticotropin-releasing hormone receptor 1 (CRH R1) in the hypoxia-induced PRL response. Hypoxia was induced by exposing the rats to high altitudes of 2 km (16.0% O2) or 5 km (10.8% O2). The PRL levels in the pituitary (iPRL) and in plasma (pPRL) were measured by immunocytochemistry and RIA assay, respectively. The acute hypoxia of 5 km for 2-24 h caused a biphasic change (early decrease and late increase) of PRL. Both CH and IH at 2 or 5 km for 1-5 days markedly increased pPRL but decreased iPRL. Continual severe hypoxia (10.8% O2) for periods of 10, 15, and 25 days significantly enhanced pPRL but this effect was less marked at the lower altitude (16.0% O2) and did not occur during intermittent hypoxia (at both altitudes). The increased pPRL was significantly enhanced by restraint, restraint + hypoxia, hypoxia, and cold + hypoxia exposure. Treatment with a CRH R1 antagonist (CP-154,526) reversed hypoxia-decreased immunoreactive PRL and upregulated PRLmRNA in the pituitary. The data suggest that both CH and IH can stimulate rat PRL release in a time-course- and intensity-dependent manner. However, compared to the relatively low CH-induced response, restraint induced a more powerful response than either cold or hypoxia alone. CRH R1 mediates PRL secretion and PRL mRNA expression in the pituitary under hypoxic exposure. Hypoxia-enhanced PRL response over the lifespan may play a significant role in adaptation to an extreme environment.

Topics: Adrenalectomy; Adrenocorticotropic Hormone; Animals; Cold Temperature; Corticotropin-Releasing Hormone; Hypoxia; Immunohistochemistry; Male; Paraventricular Hypothalamic Nucleus; Peptide Fragments; Pituitary Gland; Prolactin; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Restraint, Physical; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stress, Psychological